Piramal Pharma Solutions

Piramal Pharma Solutions PPS is a CDMO offering end-to-end development and manufacturing solutions across the drug lifecycle.

We serve our clients through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs, and Finished dosage forms. We also offer specialized services like the development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide. For more information and updates, please visit: www.piramalpharmasolutions.com

“We have set a target to reduce our Scope 1 and Scope 2 emissions by 42% by FY2030—aligned with the 1.5°C pathway recomm...
01/21/2026

“We have set a target to reduce our Scope 1 and Scope 2 emissions by 42% by FY2030—aligned with the 1.5°C pathway recommended by the Science-Based Targets initiative.”
— Peter DeYoung, CEO, Piramal Global Pharma

At Piramal Pharma Solutions, this ambition shapes how we move forward driving measurable action across our operations. From strengthening energy efficiency and climate management to embedding sustainability into drug development and manufacturing, we are continually evolving our approach to build a more responsible pharma ecosystem.

Our sustainability journey is focused on progress, accountability, and long-term impact for our partners, our communities, and the environment.

Head to the link below to watch the full interview with our CEO and learn more about our sustainability strategy.
https://youtu.be/Ltc9wiyCqD8

Selecting the right CDMO is critical for pharma innovators aiming to bring novel therapies to market. The right partner ...
01/20/2026

Selecting the right CDMO is critical for pharma innovators aiming to bring novel therapies to market. The right partner ensures high-quality delivery, regulatory compliance, and faster timelines, supporting projects from early-stage development to scalable manufacturing. ​

Piramal Pharma Solutions provides both integrated and standalone CDMO services for complex molecules, biologics, and ADCs. With deep scientific expertise, global infrastructure, and regulatory guidance, we help partners efficiently advance therapies from concept to patients. ​

Discover our latest blog to explore best practices for choosing a CDMO partner: https://www.piramalpharmasolutions.com/resources/blogs/selecting-a-cdmo-best-practices-for-pharma-innovator-companies

Since 2009, our 2.5 acre PPDS Ahmedabad facility has been a preferred partner for customers worldwide—thanks to its worl...
01/19/2026

Since 2009, our 2.5 acre PPDS Ahmedabad facility has been a preferred partner for customers worldwide—thanks to its world-class infrastructure and its strategic location within a Special Economic Zone (SEZ).​

​What this means for our customers:​
•⁠ ⁠Unmatched Cost Advantages​.
•⁠ ⁠⁠Operating within an SEZ allows us to import APIs, raw materials, consumables, and lab equipment completely duty-free—delivering significant cost savings directly to your development and clinical programs.​
•⁠ ⁠No Import Licenses Required​.
•⁠ ⁠⁠ Our SEZ status eliminates the need for import licenses for approved goods, reducing administrative steps and accelerating project timelines.​
•⁠ ⁠Faster, Smoother Customs​.
•⁠ ⁠⁠SEZ-based customs processes are streamlined, predictable, and efficient—ensuring uninterrupted material flow and faster program ex*****on.

Piramal Pharma Solutions is accelerating drug development through high-throughput experimentation (HTE), a data-driven a...
01/16/2026

Piramal Pharma Solutions is accelerating drug development through high-throughput experimentation (HTE), a data-driven approach that enables faster, more informed decision-making across discovery and early development.​

Our latest whitepaper explores how HTE allows teams to run multiple miniaturized experiments in parallel, rapidly identify optimal reaction conditions, and build robust, scalable processes often using limited starting materials.​

It highlights how well-designed HTE strategies help improve yield and purity, reduce development timelines, conserve resources, and lay a strong foundation for successful scale-up.​

Click the link below to read how high-throughput experimentation is helping accelerate R&D and advance life-changing therapies: https://business.piramalpharmasolutions.com/Experimentation_accelerates_drug_development?utm_source=HighThroughput_emailer&utm_medium=Emailer​
​

For more than 60 years, Riverview has been a cornerstone of Piramal Pharma Solutions’ drug substance manufacturing, and ...
01/14/2026

For more than 60 years, Riverview has been a cornerstone of Piramal Pharma Solutions’ drug substance manufacturing, and trusted globally for its regulatory rigor, technical depth, and experience with complex, high-potency APIs.

With decades of successful inspections across major health authorities and a strong track record of advancing HPAPIs from early development to commercial scale, Riverview continues to evolve, to meet the needs of modern drug development.
A facility shaped by experience, built to support what comes next.

To know more visit: https://www.piramalpharmasolutions.com/facilities/gmp-api-and-highly-potent-api-development-and-manufacturing-riverview

Formulating high-potency and hormonal drugs requires more than technical skill, it demands precision, robust containment...
01/13/2026

Formulating high-potency and hormonal drugs requires more than technical skill, it demands precision, robust containment, and specialized infrastructure. These capabilities are essential to ensuring operator safety, product integrity, and consistency at micro-dose levels. ​

Piramal Pharma Solutions brings decades of experience, advanced containment technologies, and integrated development-to-commercial capabilities to support partners working with these complex molecules. ​

Explore our latest blog to understand the unique challenges of HPAPI and hormonal drug formulation and how the right expertise accelerates safe, scalable manufacturing.

Read the full blog here:https://www.piramalpharmasolutions.com/resources/blogs/formulation-challenges-for-high-potency-and-hormonal-drugs

Partnerships are built through trust, dialogue, and shared ambition.Our Senior Director, Business Development Scott Alva...
01/13/2026

Partnerships are built through trust, dialogue, and shared ambition.

Our Senior Director, Business Development Scott Alvarado will be in San Francisco this January for Biotech Showcase, connecting with industry peers to explore meaningful, long-term partnerships.

Looking forward to conversations that shape what’s next.

Excited to share our latest research! Our preprint titled “Electrochemical Oxidative Cyclization: A General Sustainable ...
01/12/2026

Excited to share our latest research! Our preprint titled “Electrochemical Oxidative Cyclization: A General Sustainable Route to Indole-Oxadiazole-2-Aminesis” now available on ChemRxiv. This method utilizes inexpensive electrodes, common solvents, a range of aliphatic and aromatic isothiocyanates, demonstrating excellent functional group compatibility, medium to high yields, and a broad substrate scope.

Read the full paper here: DOI:https://chemrxiv.org/engage/chemrxiv/article-details/69394d3d08e316a05f7371ca

Keywords: Green Chemistry | Sustainable Chemistry | Electrochemical Synthesis | Oxidative Cyclization | 1,3,4-Oxadiazole-2-amines

This research was made possible thanks to the support of my team at Piramal Discovery Solutions, Ahmedabad. Looking forward to feedback and discussions from the scientific community!

chemistry

We’re proud to share that Piramal Pharma Ltd (PPL) has earned a score of 63 in the 2025 S&P Global Corporate Sustainabil...
01/12/2026

We’re proud to share that Piramal Pharma Ltd (PPL) has earned a score of 63 in the 2025 S&P Global Corporate Sustainability Assessment (CSA)—placing us in the 91st percentile within the global pharmaceutical industry.

The S&P Global CSA is one of the world’s most respected sustainability benchmarking frameworks, assessing the environmental, social, and governance practices of thousands of companies annually.

This achievement marks a 15% year-over-year improvement from our 2024 score of 55 and reflects our continued focus on sustainability, responsible operations, and long-term value creation across our businesses, including Piramal Pharma Solutions and Piramal Critical Care.

We remain committed to advancing sustainable practices that create meaningful impact for our customers, patients, and other stakeholders.

Read the full release here: https://lnkd.in/d56F6Enr

The new year begins with the conversations that matter most!Our Senior Director, Business Development Viacheslav Katin w...
01/09/2026

The new year begins with the conversations that matter most!

Our Senior Director, Business Development Viacheslav Katin will be in San Francisco this January for the Biotech Showcase, connecting with industry leaders across the biotech ecosystem.

If building meaningful partnerships and expanding networks is part of your 2026 vision, let’s connect.

Piramal Pharma Solutions is redefining project ex*****on with the POD model, an integrated, cross-functional approach de...
01/09/2026

Piramal Pharma Solutions is redefining project ex*****on with the POD model, an integrated, cross-functional approach designed for flawless delivery. ​

Our latest whitepaper explores how PODs bring together experts from multiple functions to manage projects end-to-end, with daily and weekly meetings ensuring alignment, real-time problem solving, and clear accountability.​

It highlights how digital task boards, strong leadership, and a “team-above-self” mindset enhance collaboration, speed decision making, and improve operational efficiency.​

Click the link below to read more about how PODs are transforming project delivery, empowering teams, and accelerating access to life-changing therapies: https://business.piramalpharmasolutions.com/Inside_the_POD_Whitepaper

Starting 2026 with conversations that shape what’s next in biotech!Our Director, Business Development, Daniel Weissmuell...
01/08/2026

Starting 2026 with conversations that shape what’s next in biotech!

Our Director, Business Development, Daniel Weissmueller will be attending the Biotech Showcase in San Francisco this January, connecting with biotech and pharma leaders focused on building the right partnerships for long-term success.

Let’s start the year aligned focused on building the right partnerships for long-term success.

📍 San Francisco | 12th-14th January

Address

18655 Krause Street
Riverview, MI
48193

Website

Alerts

Be the first to know and let us send you an email when Piramal Pharma Solutions posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category